Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
A multi-center phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome
In this interview, Dr. Mato discusses a Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel Bruton’s Tyrosine Kinase Inhibitor; DTRMWXHS-12 (DTRM-12), in combination with Everolimus (Afinitor®) and Pomalidomide (Pomalyst®) in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas.
Dr John Allan on new ways to target Richter’s Transformation.
Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, counts down his top ten CLL related abstract from ASCO or the American Society
Great progress has been made in treating chronic lymphocytic leukemia, but sadly the outcomes for Richter’s Transformation (RT)) or Richter’s Syndrome (RS) remain dismal. For more basic information on RT aka
Richter’s Transformation (RT) or Richter’s Syndrome (RS) remains a major unmet need in CLL. For a background on RT, please read this article by Dr. Weistner from the National Institutes of
By Brian Koffman, MD and Anthony Mato, MD As we are getting better at controlling CLL and living longer, there is increasing concern about serious late complications including Richter’s Transformation (RT)
In 1928, Dr. Richter described a patient with chronic lymphocytic leukemia (CLL), who progressed to develop an aggressive large cell lymphoma. Richter syndrome (RS), also called Richter transformation, is now understood to describe the development of an aggressive lymphoma in patients with CLL or small lymphocytic lymphoma (SLL).
New novel agents are being tested in clinical trials to help patients with CLL who have developed resistance to all the BTK inhibitors and BCL2 inhibitors.
One click to our most popular content.
